Ana Carolina Paschoalini Mafra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Carolina Paschoalini Mafra has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Alliny Cristiny da Silva Bastos
16Division of Oncology, Section of Medical Oncology, Washington University School of Medicine (WashU Medicine), St. Louis, Missouri
18 shared publications - Brian Andrew Van Tine
Washington University in St. Louis
18 shared publications - Caitlyn B. Brashears
Washington University in St. Louis 2 Saint Louis, MO
18 shared publications - Carina A. Dehner
Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia PA USA
18 shared publications - Ethan Yang Chen
Division of Medical Oncology, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, Missouri
18 shared publications - Heather M. Benedict-Hamilton
Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, USA
18 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 1
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 1